INNOVATION
IN
NANOTECHNOLOGY

We develop solutions to unsolved problems of medicine with the use of unique patent-protected nanotechnology.
Our innovations focus on human blood substitutes and targeted cancer therapies.

ABOUT NANOGROUP

NEWS

NanoGroup
Nanogroup - nanotechnology for medicine

Another stage of development of organ perfusion device completed

NanoGroup, in cooperation with A4BEE, has completed another stage of work on the NanOX Recovery Box device, designed for safe storage and perfusion of organs collected for transplantation. A4BEE delivered the third prototype of the machine, which has been fully redesigned and equipped with modern temperature control systems, power supply, software and a new frame […]

Nanogroup - nanotechnology for medicine

NanoGroup S.A. files further patent applications: for the innovative NanOX perfusion fluid and a blood substitute

NanoGroup S.A. has filed two more patent applications to the European Patent Office, via the Polish Patent Office, for patent protection for the innovative NanOX perfusion fluid and an innovative fluid for use as a blood substitute. In October, the company filed a patent application for the NanOX Recovery Box device. The first patent application […]

Nanogroup - nanotechnology for medicine

Summary of NanoGroup’s activities to date in obtaining grant funding for the development of research projects

NanoGroup S.A. finances all of its innovative research and development projects in the field of biotechnology and medicine primarily from the company’s own funds. At the same time, the group consistently strives to obtain additional sources of financing by applying for grants under grant programs that are consistent with the profile and mission of NanoGroup’s […]

MEDIA RESOURCES

NanoGroup has three
subsidiaries dedicated to
different research areas

NanoVelos Platform:
polysaccharide nanocapsules
for targeted therapies
Respiratory gases transportation systems: Blood Substitute
& NanOX System
Radioisotopes
for diagnostics & treatment

MEDICINE OF TOMORROW

NanoGroup has two development pillars, both targeting critical unsolved medical needs.

ONGOING
PLANNED

RESPIRATORY GASES
EXCHANGE FLUIDS

DISRUPTIVE INNOVATIONS

NANOVELOS PLATFORM:
POLYSACCHARIDE NANOCAPSULES
FOR TARGETED THERAPIES

EASY UPSCALING, LOWER RISK

RESPIRATORY GASES
EXCHANGE FLUIDS

DISRUPTIVE INNOVATIONS
LONG-TERM
One of the biggest unsolved of global medicine
SHORT-TERM
Disrupting change in transplantology

NANOVELOS PLATFORM:
POLYSACCHARIDE NANOCAPSULES
FOR TARGETED THERAPIES

EASY UPSCALING, LOWER RISK
New treatment opportunities with reduced development risk
ONGOING
PLANNED
SEE MORE >

CAREER

Do you set yourself ambitious scientific goals? Do you want to take part in bio-tech and nano-tech medical projects?

NanoGroup is a platform of competence and specialists who share a believe that groundbreaking technologies responding to pressing global challenges can emerge and be developed in Poland.
If you want to join our team, go ahead to contact us!

JOIN OUR TEAM
Copyright © NanoGroup 2024

Paweł Ciach

Member of the Supervisory Board of NANOGROUP S.A.

Diplomat and specialist in the marketing and media industry. Graduate of the Department of International Relations at the National Institute of Oriental Languages and Civilizations in Paris and history and sociology at the Higher School of Social Sciences at the Faculty of History in Paris. Graduate of the Diplomatic Academy (Diplomatische Akademie) in Vienna and Postgraduate Management Studies at the Faculty of Management at the University of Warsaw. Worked as a journalist, publicist, reviewer, translator and foreign correspondent. Former advisor to the president of the board for media relations at the Agricultural Market Agency and president of the board of Press-Net. Public Relations trainer, among others at: Migut Media, Knowledge, ECU International, Advertising Academy Adam Śledański. He served as director of the board office of the Association of Organizations for the Employment of Disabled Persons and president of the board of the foundation “Niezależny. Fundacja na rzecz Nieprawni”. Lecturer at the Institute of Journalism of the Warsaw School of Advertising.

Jose Arrieta

Member of the Supervisory Board of NANOGROUP S.A.

Jose Arrieta is the former Chief Information Officer and Chief Data Officer of the United States Department of Health and Human Services. He oversaw $6.3B in IT investments, $800B in grants and $26B in Federal contracts in his last three years at HHS. He provided cyber security solutions for 174,000 people and a network that transacted with over 160 countries around the world. Jose led the creation and implementation of the largest public health surveillance capability in the United States during the pandemic and led the implementation of a national supervised machine learning effort to accurately distribute testing supplies and predict pandemic “hot spots” across the United States. He successfully defended the HHS network against multiple large scale nation state driven cyber-attacks. He led the first three implementations of blockchain technology in the public sector in the United States one of which was focused on reducing costs and speeding up procurement lifecycle. Jose was a cabinet level agency executive in the following positions: deputy assistant secretary for acquisition and grants, chief information officer, chief data officer, small business executive chief acquisition executive and senior procurement executive. Jose managed the largest contracting vehicle in the United States. He created and taught the first blockchain course (blockchain and cryptos) at Johns Hopkins University and taught business courses at University of Virginia and Prince George’s Community College. He founded small incubator called imagineeer when he left Government and works with customers and advises start-ups in the following markets: healthcare, food, energy, climate change, streaming and analytics, cybersecurity, artificial intelligence, and quantum computing. He is a member of the Navy Secretary’s Science and Technology Advisory Board.

Marek Borzestowski

Member of the Supervisory Board of NANOGROUP S.A.

For many years, President of the Management Board of NanoGroup, a holding company of biotechnology companies. Entrepreneur, manager and founder of many innovative companies with over 20 years of experience as co-owner and board member in leading Polish biotechnology, IT and e-commerce companies. After over a decade of work as president of the first internet portal in Poland – Wirtualna Polska, he founded the Polish-Israeli VC Giza Polish Ventures. Founder of the Sobieski Institute think tank, Startup Hub Poland Foundation. Member of supervisory boards in many innovative companies. Marek is a graduate of the Faculty of Management and Economics of the Gdańsk University of Technology, he also studied at the University of Wales in Great Britain. He conducted scientific research at the Center for Nuclear Research in Karlsruhe and the Gdańsk University of Technology.

Artur Olender

Member of the Supervisory Board of NANOGROUP S.A.

Investor, entrepreneur and financial advisor with over 28 years of professional experience. He managed the oldest Polish brokerage company – DM Penetrator S.A. Partner in Addventure and chairman of the supervisory boards of Intersport Polska S.A., Ailleron S.A., Archicom S.A., Sotis Sp. z o.o., OTC S.A. Former advisor to the Minister of Ownership Transformations and the Minister of the Treasury in privatization processes. Active participant in many environmental and legislative initiatives for the development of the Polish capital market. He participated in the implementation of dozens of projects to raise capital on the private and stock exchange market. He introduced to the stock exchange, among others, Mostostal Warszawa, Odlewnie Polskie, Poligrafia, WSiP, Polmos Białystok, Intersport, K2, Inteliwise, Cyfrowy Polsat, OT Logistic, Mercator Medical, Ailleron and Archicom. He studied at AGH and London Business School. Privately: windsurfer, sailor, skier, traveler, poet, composer and philanthropist.

Tadeusz Wesołowski

Member of the Supervisory Board of NANOGROUP S.A.

A well-known investor focused on companies from the medical and biotechnology industries. He has extensive professional experience in the healthcare sector. Founder of Prosper S.A., which is part of the NEUCA S.A. Capital Group – the leader of the pharmaceutical distribution market in Poland. Member of the supervisory boards of companies listed on the Warsaw Stock Exchange: NEUCA, Selvita and Braster. He is also involved in Venture Capital funds: Inovo and Experior. Doctor of Technical Sciences, graduate of the Warsaw University of Technology.

Robert Dziubłowski

Member of the Supervisory Board of NANOGROUP S.A.

Co-founder of Top Consulting S.A., one of the oldest consulting companies on the Polish market. He has over 25 years of international experience in the field of investment consulting, capital raising for companies, market acquisitions and company management. Long-time consultant to American financial organizations on Wall Street in New York, including those listed on the NASDAQ and NYSE stock exchanges. He advised, among others: Household International in preparing an acquisition strategy and obtaining a banking license in Poland, Wussler Group, a partner of Ted Turner Pictures in its attempt to take over NTV, the largest private television station in Russia, Eiffage Construction in the takeover of Mitex, the largest construction company at that time, Industrial Union of Donbas, an industrial group in Ukraine. Member, chairman and president of supervisory boards of many companies listed on the Warsaw Stock Exchange, including: Bauma S.A. (currently ULMA S.A.), Computerland Poland S.A. (currently Signity), PolAqua S.A. Co-founder of the Start-up Hub Poland Fund. Graduate of the Faculty of Journalism and Political Science at the University of Warsaw and International Relations at the University of Hawaii in Honolulu.

Jerzy Garlicki

President of the Supervisory Board of NANOGROUP S.A.

Medical doctor, also completed MBA, effective manager. Organizer of business model and company structures – experienced in building and developing companies and conducting restructuring processes of enterprises. In the past director and motivator of large companies and teams of people. A man recognizable as a leader in the Polish pharmaceutical industry. Member of the Supervisory Board of American Heart of Poland SA and President of WSiP SA. Previously President of Astra Zeneca Sp. z o.o., President of Fournier Polska Sp. z o.o., Sales Director of Pfizer Polska Sp. z o.o., Sales Director and Marketing Director of MSD Poland – also operating in the area of clinical trials.

Prof. Tomasz Ciach

Founder, Member of the Management Board of NANOGROUP S.A.

Nanotechnology expert. Professor at the Faculty of Chemical and Processing Engineering, Warsaw University of Technology, head of the Biotechnology and Bioprocessing Division. Author of two technologies that are already in production stage, 12 granted patents and over 50 publications. Founder of BioMedLab research group, consultant in numerous companies (AstraZeneca, Procter and Gamble, Reckit, Adamed, Balton, Galmed). Work on various aspects of Biomedical Engineering, mostly on biomedical nanotechnology, active coatings for medical implants, nanoparticles for cancer treatment, biodegradable and nonbiodegradable implants, bone and vascular prosthesis. He gives rare, but already brilliant example of how brave ideas become socially and financially valuable.

Piotr Mierzejewski

Vice President of the Management Board of NANOGROUP S.A.

Clinical pharmacology specialist, former advisor to the Minister of Health on drug policy. He negotiated Poland’s accession to the EU in the field of pharmacy, responsible for the implementation of EU directives in the field of pharmacy into the Polish legal system. Co-founder of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products. Owner of a consulting company cooperating with international pharmaceutical companies in the field of introducing new technologies to the Polish market.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.

Przemysław Mazurek

President of the Management Board of NANOGROUP S.A.

Associated with the health market since 2004. As Managing Director, he restructured and developed the most dynamically operating Medical Center in the Podkarpacie region, creating and setting new standards of customer service quality on the market. Co-creator of the first solution in Poland for online registration of medical appointments. Co-founder of the first and only Infertility Treatment Clinic (MEDICOR) in Podkarpacie, which he headed as the President until 2009. He was responsible for the development of health insurance in the PZU Group. As Vice President of PZU Pomoc S.A. created the largest medical TPA in Poland to handle health insurance. Co-founder of the first drug insurance in Poland. Since 2015, he has been active in the field of Wealth Management and advises on management and finance. A graduate of International Economic and Political Relations as well as Management and Marketing at the Warsaw School of Economics.